Unique metastasis‐associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma

Autor: Guixi Zheng, Mingjin Zou, Lutao Du, Jing Hao, Xiaoli Li, Xin Zhang, Yujiao Xie, Xiaoshi Zhang, Jingyi Han, Chuanxin Wang, Weili Duan, Lili Wang, Yinghui Zhao
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Oncology
Lung Neoplasms
Metastasis
0302 clinical medicine
General Medicine
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Gene Expression Regulation
Neoplastic
Survival Rate
medicine.anatomical_structure
Lymphatic Metastasis
030220 oncology & carcinogenesis
Adenocarcinoma
Female
RNA
Long Noncoding
Original Article
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Adenocarcinoma of Lung
TNM staging system
lcsh:RC254-282
03 medical and health sciences
Internal medicine
Cancer genome
Biomarkers
Tumor
medicine
Humans
metastasis
Lung cancer
Survival analysis
Aged
Neoplasm Staging
Lung
Receiver operating characteristic
lncRNA signature
business.industry
Gene Expression Profiling
Original Articles
prediction
lung adenocarcinoma
medicine.disease
030104 developmental biology
ROC Curve
prognosis
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: Thoracic Cancer, Vol 11, Iss 3, Pp 728-737 (2020)
Thoracic Cancer
ISSN: 1759-7714
1759-7706
Popis: Background Local relapses and metastases are primary causes of death in lung cancer patients. In the present study, we aimed to develop a prognostic signature based on metastasis‐associated lncRNAs in patients with lung adenocarcinoma (LUAD). Methods Firstly, the potential metastasis‐associated lncRNAs were identified by analyzing high‐throughput data from The Cancer Genome Atlas (TCGA), and based on which, an lncRNA signature was constructed for prediction of relapse in LUAD patients using Cox proportional hazards regression analysis. Moreover, the prognostic performance of the lncRNA signature was evaluated using Kaplan‐Meier survival analysis, time‐dependent receiver operating characteristic (ROC) curve and Cox analysis, respectively. In addition, the potential metastasis‐associated function of these six lncRNAs was confirmed by lncRNA over‐expression or depletion and in vitro transwell assays in LUAD cells. Results An lncRNA signature consisting of six most important prognostic factors (LINC01819, ZNF649‐AS1, HNF4A‐AS1, FAM222A‐AS1, LINC02323 and LINC00672) was developed. The signature was an independent predictor for patients' relapse‐free survival (RFS), which could provide higher tumor relapse prediction capability compared with the TNM staging system at three years and five years, respectively (P = 0.0209 and P = 0.0468). Furthermore, the combination of this lncRNA signature and TNM stage had better prognostic value than TNM stage alone at three and five years, respectively (P = 0.0006 and P = 0.0096). Additionally, all the lncRNAs of the signature had a regulatory role in the LUAD cell mobility. Conclusions This novel six‐lncRNA signature had considerable prognostic value for prediction of relapse in LUAD patients. Key points Significant findings of the study The unique metastasis‐associated lncRNA signature was related to tumor metastasis and prognosis in LUAD patients. What this study adds This signature had considerable prognostic value for prediction of relapse in LUAD patients.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje